关爱白癜风健康惠民活动 http://m.39.net/pf/a_5777826.htmlTODAY今日发布JCardiovascMagnResonDec01,:21(1)今日发布01篇（共计34篇）BMCCardiovascDisordDec01,:19(1)今日发布01篇（共计篇）CurrCardiolRepAug01,:21(8)今日发布01篇（共计09篇）IntJCardiovascImagingEarlyRecent,June26,今日发布01篇ATVBJuly01,:39(7)今日发布24篇CurrHeartFailRepEarlyRecent,June27,今日发布01篇StrokeEarlyRecent,June27,今日发布05篇CirculationEarlyRecent,June27,今日发布02篇RECOMMEND推荐阅读01血管生成素样蛋白3(ANGPTL3)单克隆抗体可降低甘油三酯血症患者的甘油三酯水平Circulationresearch-articleZahidAhmad,PoulabiBanerjee,etc.3小时前等30用户推荐阅读本文Background:Hypertriglyceridemiaisassociatedwithincreasedcardiovascularriskandmaybecausedbyimpairedlipoproteinclearance.Angiopoietin-likeprotein3(ANGPTL3)inhibitslipoproteinlipaseactivity,increasingtriglyceridesandotherlipids.Evinacumab,anANGPTL3inhibitor,reducedtriglyceridesinhealthyhumanvolunteersandinhomozygousfamilialhypercholesterolemicindividuals.Resultsfrom2Phase1studiesinhypertriglyceridemicsubjectsarereportedhere.高甘油三酯血症与心血管风险增加有关，可能由脂蛋白清除受损引起。血管生成素样蛋白3（angptl3）抑制脂蛋白脂酶活性，增加甘油三酯和其他脂质。Evinacumab是一种Angptl3抑制剂，在健康的人体志愿者和纯合型家族性高胆固醇个体中降低甘油三酯。本文报告了高甘油三酯受试者的2项1期研究结果。Methods:Subjectswithtriglyceridesbut≤mg/dLandLDL-C≥mg/dL(n=83forsingleascendingdosestudy[SAD];n=56formultipleascendingdosestudy[MAD])wererandomized3:1toevinacumab:placebo.SADsubjectsreceivedevinacumabsubcutaneously(SC)at75//mg,orintravenously(IV)at5/10/20mg/kg,monitoreduptoday(d).MADsubjectsreceivedevinacumabSCat//mgonceweekly,/mgevery2weeks,orIVat20mg/kgonceevery4weeks(Q4W)uptod56with6monthsoffollow-up.Theprimaryout
转载请注明：http://www.baibanguangwang.com/jbgs/22889.html
